This study is in progress, not accepting new patients
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Allogene Therapeutics
- ID
- NCT03939026
- Phase
- Phase 1 Lymphoma Research Study
- Study Type
- Interventional
- Participants
- Expecting 74 study participants
- Last Updated